FAS093 significantly inhibited tumors from human NSCLC

[RandyW]

FASgen Announces New Research Discoveries in Lung Cancer

BALTIMORE, Dec. 28 /PRNewswire/ -- FASgen is pleased to report the

publication of important research results for lung cancer treatment using

FAS093, one of the Company's proprietary compounds. In a long-standing

cooperation with The Johns Hopkins Oncology Center, FASgen supported

research into the selective inhibition of fatty acid synthase (FASi) at the

Hopkins Oncology Center as a potential therapeutic agent against various

forms of solid tumor cancers. In the recently reported study results,

researchers at the Hopkins Oncology Center found that FAS093 significantly

inhibited growth of several different xenograft tumors from human NSCLC

cell lines. These extremely interesting results appear in the article,

"Selective Inhibition of Fatty Acid Synthase for Lung Cancer Treatment,"

Gabrielson et al, Clin Cancer Res 200l, 13(23) 7139-7145 (Dec. 1, 2007).

About FASgen, Inc.: FASgen, Inc. is a drug development company founded

in 2000 by four distinguished Johns Hopkins researchers to create new

therapeutic products based on the selective inhibition of fatty acid

biosynthesis. The Company has the exclusive license from Johns Hopkins to

more than 15 years of research in the field, which research continues under

a sponsored research agreement with the University.

The Company has designed and synthesized many compounds that

selectively inhibit fatty acid biosynthesis. One group of these compounds

holds great promise for new highly specific therapeutics for cancer;

additional compounds have the potential of specific therapeutics for

obesity and related metabolic disorders; and, an additional group of

compounds have the potential of specific therapeutics for TB, including

multiple drug resistant TB (MDR-TB) and latent TB infections that affect

one third of the world's population. For more information, visit FASgen's

website at http://www.fasgen.com